23602-98-4

Usage

Uses

Used in Organic Chemistry:
Dibenzo[b,d]furan-2-sulfonyl chloride is used as a reactive intermediate for the synthesis of various chemical compounds. Its sulfonyl functional group allows it to participate in reactions with nucleophiles, making it a versatile building block in the creation of complex organic molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, dibenzo[b,d]furan-2-sulfonyl chloride is used as a key component in the synthesis of certain drugs. Its reactivity with nucleophiles enables the formation of new bonds and the construction of drug molecules with desired therapeutic properties.
Used in Material Science:
Dibenzo[b,d]furan-2-sulfonyl chloride is employed in material science as a precursor for the development of novel materials with specific properties. Its involvement in chemical reactions can lead to the creation of materials with tailored characteristics, such as improved stability or enhanced reactivity.
Used in Research and Development:
In research and development settings, dibenzo[b,d]furan-2-sulfonyl chloride is used as a tool to explore new chemical reactions and pathways. Its reactivity with nucleophiles provides a platform for investigating the mechanisms of various chemical processes and for discovering new synthetic strategies.

InChI:InChI=1/C12H7ClO3S/c13-17(14,15)8-5-6-12-10(7-8)9-3-1-2-4-11(9)16-12/h1-7H

Upstream product

• 83863-63-2 2-Dibenzofuransulfonic acid 
• 132-64-9 dibenzofuran 

Downstream Products

• 147224-77-9 dibenzofuran-2-sulfonic acid anilide 
• 203640-01-1 (R)-2-(Dibenzofuran-2-sulfonylamino)-3-(1H-indol-3-yl)-propionic acid benzyl ester 
• 1026008-71-8 dibenzofuran-2-sulfonic acid (4-iodo-phenyl)-amide 
• 501683-00-7 (E)-3-[4-(Dibenzofuran-2-sulfonylamino)-phenyl]-acrylic acid 
• 210532-14-2 N-[3,5-Dimethyl-4-[(nitromethyl)sulphonyl]phenyl]-2-dibenzofuransulphonamide 
• 109503-14-2 thiobenzoic acid S-dibenzofuran-2-yl ester 
• 1628741-17-2 C₂₂H₁₆ClNO₄S 
• 1628741-42-3 3-azido-N-(4-chlorophenyl)-2-(dibenzo[b,d]furan-2-yl)-2-methylpropanamide 
• 186550-42-5 Dibenzofuran-2-sulfonic acid [1-(3-cyanobenzyl)-2-oxo-pyrrolidin-3-(S)-yl]-amide 
• 186550-23-2 dibenzofuran-2-sulfonic acid [1-(3-cyanobenzyl)-5-oxo-pyrrolidin-3-yl]-amide 

Relevant academic research and scientific papers

Synthesis and biological activity of various derivatives of a novel class of potent, selective, and orally active prostaglandin D2 receptor antagonists. 1. Bicyclo[2.2.1]heptane derivatives

Novel prostaglandin D2 (PGD2) receptor antagonists were synthesized as a potential new class of antiallergic agents having a bicyclo[2.2.1] heptane ring system with sulfonamide groups. Some of them exhibit extremely potent antagonism of the PGD2 receptor in radioligand binding and cAMP formation assays with IC50 values below 50 nM and much less antagonism of TXA2 and PGI2 receptors. These potent PGD2 receptor antagonists, when given orally, dramatically suppress various allergic inflammatory responses such as increased vascular permeability in allergic rhinitis, conjunctivitis, and asthma models. The excellent pharmacological profiles of PGD2 receptor antagonists, originally synthesized in our laboratories, are of potentially great clinical significance. This study also provides experimental evidence suggesting that PGD2 plays an important role in the pathogenesis of allergic diseases.

Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin

Biphenylsulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, bicyclic or tricyclic carbon or heterocyclic ring biphenylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.

N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin

Thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.

Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives

Various N-sulfonylamino acid derivatives were synthesized and evaluated for their in vitro and in vivo activities to inhibit type IV collagenase (MMP-9 and MMP-2). When the amino acid residue and the sulfonamide moiety were modified, their inhibitory activities were greatly affected by the structure of the sulfonamide moiety. A series of aryl sulfonamide derivatives containing biaryl, tetrazole, amide, and triple bond were found to be potent and highly selective inhibitors of MMP-9 and MMP-2. In addition, these compounds were orally active in animal models of tumor growth and metastasis. These results revealed the potential of the N-sulfonylamino acid derivatives as a new type of candidate drug for the treatment of cancer.

THIENYL-, FURYL- AND PYRROLYL SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN

Thienyl-, furyl-and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl) furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.

CHLOROSULFONATION OF SOME POLYNUCLEAR HETEROCYCLIC COMPOUNDS

Dibenzofuran (1), dibenzothiophene (20) and the 5,5-dioxide (29), carbazole (43) and fluorene (50) have been reacted with chlorosulfonic acid.The resultant sulfonyl chlorides (2, 12, 18, 21, 23, 27, 30, 37, 44, 46 and 51) were condensed with amines and hy